Comments on: Laboratory tests for the management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants: Proposals of the Working Group on Perioperative Haemostasis (GIHP)

Archives of Cardiovascular Diseases

Volumn 107, Issue 5, 2014, Pages 345-346

  Tripodi, Armando ^a   Di Minno, Dario ^b   Moia, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Direct oral anticoagulants; Laboratory tests; Surgery

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; PROTHROMBIN; RECOMBINANT THROMBOPLASTIN; RIVAROXABAN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; COAGULATING AGENT;

BLOOD CLOTTING TEST; DRUG BLOOD LEVEL; DRUG CONCENTRATION; EMERGENCY SURGERY; HUMAN; LABORATORY TEST; LETTER; OPERATIVE BLOOD LOSS; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; BLOOD CLOTTING; DRUG EFFECTS; HEMORRHAGE; HEMOSTASIS; SURGERY;

ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; COAGULANTS; FACTOR XA INHIBITORS; HEMORRHAGE; HEMOSTATIC TECHNIQUES; HUMANS; SURGICAL PROCEDURES, OPERATIVE;

EID: 84903267948     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2014.04.003     Document Type: Letter

References (10)

1. G. Pernod, P. Albaladejo, A. Godier, C.M. Samama, S. Susen, and Y. Gruel et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013 Arch Cardiovasc Dis 106 2013 382 393
2. European Medicine Agency. Annex I, dabigatran summary of product characteristics. Accessed at http://www.ema.europa.eu/.
3. European Medicine Agency. Annex I, rivaroxaban summary of product characteristics. Accessed at http://www.ema.europa.eu/.
4. J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain, and J.M. Dogné Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate Thromb Haemost 107 2012 985 997
5. A. Hillarp, F. Baghaei, I. Fagerberg Blixter, K.M. Gustafsson, L. Stigendal, and M. Sten-Linder et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays J Thromb Haemost 9 2011 133 139
6. T.L. Lindahl, F. Baghaei, I.F. Blixter, K.M. Gustafsson, L. Stigendal, and M. Sten-Linder et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays Thromb Haemost 105 2011 371 378
7. M.M. Samama, J.L. Martinoli, L. LeFlem, C. Guinet, G. Plu-Bureau, and F. Depasse et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor Thromb Haemost 103 2010 815 825
8. E.M. Hawes, A.M. Deal, D. Funk-Adcock, R. Gosselin, C. Jeanneret, and A.M. Cook et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels J Thromb Haemost 11 2013 1493 1502
9. R. Rodgers, C.N. Bagot, C. Lawrence, G. Hickman, M. McGurk, and R.C. Tait Correlating prothrombin time with plasma rivaroxaban level Br J Haematol 163 2013 685 687
10. J.J. van Veen, J. Smith, S. Kitchen, and M. Makris Normal prothrombin time in the presence of therapeutic levels of rivaroxaban Br J Haematol 160 2013 859 861